x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Base to Base Biotech

The Base to Base Biotech podcast is a weekly look at what"s happening in the world of biotech, with interviews with biotech leaders around the world.Whether it"s a new drug, cutting-edge technology, product launches, new technology, major finding announcement or clinical trial results, Base to Base Biotech keeps you informed.The podcast is hosted by former biotech editor and broadcaster, the award-winning media veteran Jim Cornall.Base to Base is an Ayr Coastal Media Ltd production.

health & fitness medicine

All Episodes

53:30

Base to Base biotech podcast 41: Eyes, mitochondria...

Base to Base Biotech ·

2026/01/09

This week, we’re talking about eye treatments with Oculis CEO, Riad Sherif, we have a conversation about mitochondria, with the CEO of Vandria, Klaus Dugi, and there’s also a short discussion about GoCo Health Innovation City in Gothenburg, Sweden, with Moa Dicksdotter, Partnership and Ecosystem.Times:02:35 Vandria20:03 GoCo Health Innovation City25:54 OculisLooking to the eyesOculis is a Swiss ophthalmology company developing topical and biologic treatments for retinal disease and neuro‑ophthalmic

en

69:32

Base to Base biotech podcast 40: Anchored...

Base to Base Biotech ·

2025/12/19

This week, we’re talking about skin and wounds, with Ned Swanson, president and chief medical officer at PolarityBio, and Nikolai Sopko, chief operating officer, chief scientific officer and director at PolarityBio; and we discuss anchored immunotherapy with Howard Kaufman, CEO of Ankyra Therapeutics.04:03 Ankyra Therapeutics34:31 PolarityBioAnchored immunotherapiesAnkyra Therapeutics, based in Cambridge, Massachusetts, develops anchored immunotherapies that tether cytokines at the injection site to

en

66:20

Base to Base biotech podcast 39: Gene therapy for eye...

Base to Base Biotech ·

2025/12/12

This week, we have conversations with Jakob Andersson, vice president of engineering at Anaphora and founder and chairman of GAIA; Coave Therapeutics’ CEO Rodolphe Clerval; and MOBILion Systems’ CEO, Melissa Sherman.Times:03:13 Coave Therapeutics 24:43 GAIA Conference 36:55 MOBILion SystemsGenetic medicine for ophthalmologyCoave Therapeutics is a Paris‑based biotechnology company focused on developing genetic medicines using its ALIGATER platform. The company has pioneered ligand‑conjugated AAV

en

79:02

Base to Base biotech podcast 38: Obesity, life...

Base to Base Biotech ·

2025/12/05

This week, we have conversations with Sjanna Bosma, international relations officer at Health Holland; Mark Bagnall, CEO of Phenomix; and PDS Biotechnology CEO Frank Bedu-Addo.04:17 Phenomix 32:53 Health Holland 44:02 PDS BiotechnologyPhenomix takes on obesityPhenomix Sciences is a biotechnology company focused on precision obesity medicine. The firm has developed the MyPhenome test, a saliva‑based assay that uses machine‑learning algorithms and genetic risk scores to classify obesity phenotypes and

en

64:59

Base to Base biotech podcast 37: Life Sciences in...

Base to Base Biotech ·

2025/11/28

This week, we have conversations with Jérôme Van Biervliet, chair of the board of Flanders life sciences body Biovia and managing director at VIB; Sylvain Sachot, partner at Asabys Partners; and Jonas Béal, head of science strategy, R&D, at Owkin.03:32 Owkin 27:42 Biovia/VIB 38:06 Asabys PartnersBiovia/VIBBiovia has emerged as a new health innovation cluster in the Belgian region of Flanders, created through the merger of flanders.bio and MEDVIA.The organisation brings together more than 450

en

77:17

Base to Base biotech podcast 36: Life science in...

Base to Base Biotech ·

2025/11/21

This week, we have conversations with Robert Bunn, founder and president of Ultrasound AI; Laura MacNeill, CEO of the Charcot Marie Tooth Research Foundation; and Iris Örhn, investment advisor at Business Region Göteborg.03:00 Ultrasound AI 30:19 Business Region Gothenburg 39:35 CMTRFBusiness Region GothenburgBusiness Region Gothenburg (BRG) is the regional development agency for western Sweden, tasked with driving growth and innovation across key sectors, including life sciences. Its work spans

en

50:33

Base to Base biotech podcast 35: Gothenburg Tech...

Base to Base Biotech ·

2025/11/14

This week, we have conversations with Malin Kjällström, Gothenburg Tech Week Press and partnerships lead; Eliot Forster the CEO of Levicept; and Christophe Demaison, CEO of ENA Respiratory.Gothenburg Tech WeekGothenburg Tech Week is western Sweden’s largest technology event, held annually across multiple venues in the city. The 2025 edition ran from October 14–16, with a programme that includes startup and investor matchmaking, thematic forums, and partner showcases.The event covers a wide range of

en

62:00

Base to Base biotech podcast 34: World Immunization...

Base to Base Biotech ·

2025/11/07

It’s World Immunization Day on Monday, so we had a chat with Geovax chairman, president and CEO David Dodd, and in our other conversation, we talked about infertility, with Igyxos Biotherapeutics’ chief medical officer Elke Bestel.Challenging infertilityIgyxos Biotherapeutics is a French biotechnology company founded in 2017 and based in Nouzilly, France. The company focuses exclusively on infertility, developing monoclonal antibody‑based therapeutics designed to enhance the activity of

en

59:09

Base to Base biotech podcast 33: Pain relief, fungi...

Base to Base Biotech ·

2025/10/31

This week, we have conversations with Cosmo Feilding Mellen, CEO of Beckley Psytech; Sirli Rosenvald, CEO of Estonian company Funki, and Per von Mentzer, CEO of Swedish company PharmNovo. We spoke with Funki at Life Sciences Baltics in Vilnius, Lithuania, recently, and with von Mentzer at NLS Days in Gothenburg.Taking on painPharmNovo AB is a biotechnology company headquartered at Medicon Village in Lund, Sweden. Founded in 2008, it specialises in the development of novel treatments for neuropathic

en

60:27

Base to Base biotech podcast 32: Multi-omics data and...

Base to Base Biotech ·

2025/10/24

This week, we have conversations on data integration with Lithuanian company Vugene, and we talk protein degradation with Amphista Therapeutics.Multi-omicsVugene is a Lithuanian bioinformatics company focused on multi-omics data integration. Founded in 2021 by CTO Juozas Gordevičius, the company is headquartered in Kaunas.Its core offering is a software platform designed to help researchers make sense of complex biological datasets — including transcriptomics, proteomics, metabolomics, and

en

44:59

Base to Base biotech podcast 31: Exhilarating enzymes...

Base to Base Biotech ·

2025/10/17

This week, we have one interview, covering enzymes and AI with Biomatter Designs, from our visit to Life Sciences Baltics in Vilnius, Lithuania recently. And from the trip to Dublin in Ireland we talked about technology that can be useful in neurological condition diagnosis, and much more, with Danu Sports.Enzymes and AIBiomatter Designs is a Lithuania‑based biotech working at the frontier of protein design. Since its launch in 2018, the company has concentrated on building tools that use artificial

en

51:02

Base to Base biotech podcast 30: Life sciences in...

Base to Base Biotech ·

2025/10/09

This week, we have three interviews done during Life Sciences Baltics, which was held in Vilnius, Lithuania recently. While we have more still to come, this week on the podcast we have conversations with Justinas Mačiulaitis, Keli Therapeutics’ founder and CEO; Arnas Karužas, CEO of Ligence; and Emilė Radytė, CEO and co-founder of Samphire Neuroscience.LigenceLigence is a health‑tech startup using artificial intelligence to automate echocardiography.Founded in 2019 by a team of medical doctors and

en

57:12

Base to Base biotech podcast 29: Blood pressure and...

Base to Base Biotech ·

2025/10/03

This week, we have two interviews again. We talk about treating high blood pressure with CEO of George Medicines, Mark Mallon, and have a conversation with Jack Hoppin, CEO of Ratio Therapeutics, and John Babich, CSO, about the field of radiotherapeutics.Blood pressureNearly half of US adults have high blood pressure and despite all the treatments already available, three in four remain uncontrolled. This is often because the traditional stepwise treatment approach stalls before reaching target

en

49:40

Base to Base biotech podcast 28: CTPS1 and ocular...

Base to Base Biotech ·

2025/09/25

This week, we have two interviews. We chat with Step Pharma CEO, Andy Parker, and also have a conversation with Re-Vana CEO, Michael O’Rourke.Ocular therapeuticsRe-Vana Therapeutics and Boehringer Ingelheim recently announced a $1bn+ deal to develop long-acting ophthalmic therapies.Re-Vana Therapeutics is a privately held, US and UK based developer of ocular therapeutics and innovative ocular drug delivery technologies which spun out of Queens University Belfast, Northern Ireland.Terms of the deal

en

54:03

Base to Base biotech podcast 27: Childhood Cancer...

Base to Base Biotech ·

2025/09/19

This week, we have two interviews: one to mark Childhood Cancer Awareness Month, on osteosarcoma with Paul Romness from OS Therapies; and IMUNON’s CEO, Stacy Lindborg, talking about ovarian cancer, immunotherapy, covid, and more.Interview times:02:33 OS Therapies23:03 IMUNONChallenging osteosarcomaOS Therapies is a clinical stage oncology company focused on the identification, development, and commercialisation of treatments for osteosarcoma (OS) and other solid tumours. OST-HER2, the company's lead

en

58:45

Base to Base biotech podcast 26: Stand Up To Cancer Day

Base to Base Biotech ·

2025/09/12

This week, we have three interviews to mark Stand Up To Cancer Day. We have conversations with Simon Kerry, co-founder and CEO of Curve Therapeutics; Poolbeg Pharma CEO Jeremy Skillington; and Stefano Gulla, CSO of Kling Biotherapeutics.Interview times:03:12 Curve Therapeutics21:32 Kling Bio37:10 Poolbeg PharmaMicrocycles to address cancerCurve Therapeutics, a private biotechnology company using its gene-encoded Microcycle discovery platform to build a pipeline of innovative cyclic peptide and small

en

39:44

Base to Base biotech podcast 25: Molecular glue...

Base to Base Biotech ·

2025/09/05

This week, we have an in-depth conversation on molecular glue degradation, with Monte Rosa Therapeutics’ chief data and information officer John Castle.Interview time:03:52 Monte Rosa TherapeuticsMolecular glue degradationA recent cover article in Science showcased research that expands by more than 1,000 the number of therapeutic targets (including undruggables) accessible through a protein degradation approach known as molecular glue degradation.Using proprietary AI and ML approaches, researchers

en

46:25

Base to Base biotech podcast 24: Dissecting the US...

Base to Base Biotech ·

2025/08/29

This week, we look at Herantis Pharma's work on Parkinson's disease, with the company's CEO, Antti Antti Vuolanto, and we have an in-depth look at the recent cuts to mRNA vaccine projects, with Jean Peccoud, GenoFAB founder and professor at Colorado State University.Interview times: 03:22 Herantis 16:28 mRNA cutsCuts to mRNA vaccine projectsThe U.S. Department of Health and Human Services (HHS) recently announced a major shift in its vaccine development priorities, initiating a “co‑ordinated

en

47:21

Base to Base biotech podcast 23: Digitalisation in...

Base to Base Biotech ·

2025/08/22

This week, we have a wide-ranging conversation with Anna Codina, senior director strategy and business development at SciY (part of Bruker), as we discuss artificial intelligence, and digitalisation, and the effect on labs. We also chat with Fibrobiologics’ CEO Pete O'Heeron about fibroblast spheroid technology.Interview times:03:49 FibroBiologics21:26 SciYSciY on the path to digitalisationThis week, we have a wide-ranging conversation with Anna Codina, senior director strategy and business

en

47:48

Base to Base biotech podcast 22: A new treatment for...

Base to Base Biotech ·

2025/08/15

This week, we talk about new treatments for wet dry age-related macular degeneration (AMD) with Judith Greciet, CEO of PulseSight Therapeutics, and there’s a conversation with Maite Agüeros, CEO and co-founder of InnoUp Farma about, among other things, peanut allergies.Interview times: 03:24 PulseSight 20:43 InnoUpTackling dry AMDPulseSight Therapeutics SAS, an ophthalmology biotech company developing non-viral vectorised therapies with minimally-invasive delivery technology, recently announced the

en

41 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

The Dry Eye Treatment PODCAST

Dry Eye Treatment

Différent et alors ?

PATRICK SULAY

Kyle Kingsbury Podcast

Kyle Kingsbury

The Real Weight Loss Coach

Matty Lansdown